

# Prophylactic Effect of Ivermectin on SARS-CoV-2 Induced Disease in a Syrian Hamster Model

Takayuki Uematsu (✉ [tuematsu@insti.kitasato-u.ac.jp](mailto:tuematsu@insti.kitasato-u.ac.jp))

Kitasato University Medical Center

Tomomi Takano

Department of Veterinary Medicine, Kitasato University

Hidehito Matsui

Ōmura Satoshi Memorial Institute, Kitasato University

Noritada Kobayashi

Kitasato University Medical Center

Hideaki Hanaki

Ōmura Satoshi Memorial Institute, Kitasato University

---

## Article

### Keywords:

**Posted Date:** September 15th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-2012940/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

COVID-19, caused by SARS-CoV-2 infection, is currently among the most important public health concerns worldwide. Although several effective vaccines have been developed, there is an urgent clinical need for effective pharmaceutical treatments for treatment of COVID-19. Ivermectin, a chemical derivative of avermectin produced by *Streptomyces avermitilis*, is a macrocyclic lactone with antiparasitic activity. Recent studies have shown that ivermectin inhibits SARS-CoV-2 replication *in vitro*. In the present study, we investigated the *in vivo* effects of ivermectin in a hamster model of SARS-CoV-2 infection. The results of the present study demonstrate oral administration of ivermectin prior to SARS-CoV-2 infection in hamsters was associated with decreased weight loss and pulmonary inflammation. In addition, the administration of ivermectin reduced pulmonary viral titers and mRNA expression level of pro-inflammatory cytokines associated with severe COVID-19 disease. The administration of ivermectin rapidly induced the production of virus-specific neutralizing antibodies in the late stage of viral infection. Zinc concentrations leading to immune quiescence were also significantly higher in the lungs of ivermectin-treated hamsters compared to controls. These results indicate that ivermectin may have efficacy in reducing the development and severity of COVID-19 by affecting host immunity in a hamster model of SARS-CoV-2 infection.

## Introduction

The first case of COVID-19 (coronavirus disease 2019) infection caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) was confirmed in China in November 2019. More than two years later, COVID-19 infection has shown no signs of abatement and has become a major public health concern around the world. COVID-19 infection is not a fulminant infection such as viral hemorrhagic fever but can progress to severe respiratory failure and thrombosis, potentially leading to death<sup>1,2</sup>. In addition, cases of long-lasting sequelae such as chronic fatigue, alopecia, circulatory disturbances, and olfactory and gustatory disturbances after recovery have been reported<sup>3,4</sup>. Several vaccines have been developed for the prevention of COVID-19 infection with proven efficacy<sup>5,6</sup>. However, vaccines require significant development time before being readily available to all suitable recipients. Moreover, the efficacy of vaccines against certain mutant SARS-CoV-2 strains may be attenuated<sup>7</sup>. Studies have also shown that the protection conferred by vaccines against SARS-CoV-2 infection begins to decline several months after the second vaccination, with the risk of breakthrough infection gradually increasing from 90 days after the second vaccination<sup>8</sup>. In addition, despite the active global development of COVID-19 therapeutics, few drugs have demonstrated consistent efficacy. As the global spread of COVID-19 infection remains unabated, there is a need for inexpensive and safe antiviral drugs with prophylactic and therapeutic effects that can be made available worldwide independently of the medical environment.

Ivermectin, a chemical derivative of avermectin produced by *Streptomyces avermitilis*, is a macrocyclic lactone with antiparasitic activity in oral administration<sup>9,10</sup>. Recent studies have shown that ivermectin inhibits the replication of SARS-CoV-2 *in vitro*<sup>11</sup>. Accordingly, clinical trials evaluating the potential of

ivermectin as a COVID-19 treatment are now being conducted worldwide. However, there is currently a lack of good-quality evidence supporting the use of ivermectin for the treatment or prevention COVID-19, as demonstrated in a recent Cochrane systematic review<sup>12</sup>.

In the present study, we evaluated the *in vivo* effects of ivermectin and developed a SARS-CoV-2 infection model using Syrian hamsters, which are a popular rodent model for COVID-19<sup>13–15</sup> to determine the prophylactic effects of ivermectin administration on COVID-19. Ivermectin was administered prophylactically to determine the therapeutic efficacy of ivermectin in Syrian hamsters infected with SARS-CoV-2.

## Results

### Prophylactic administration of ivermectin prevents weight loss in a hamster model of SARS-CoV-2 infection

We preliminarily investigated ivermectin administration routes and dosages by determining the dose required to inhibit weight loss after SARS-CoV-2 infection in a hamster model. The clinical dose of ivermectin in humans is 150–400 µg/kg<sup>9,10</sup>. Therefore, hamsters were infected with SARS-CoV-2 after administration of a single dose of ivermectin at 250 µg/kg or 500 µg/kg. However, an inhibitory effect on weight loss after SARS-CoV-2 infection was not observed at these concentrations with oral or intraperitoneal administration (Supplementary Fig. 1a,b). Based on the results of the preliminary study, ivermectin was prepared with 5% ethanol (w/v), 10% polyethylene glycol (PEG) 400 (w/v), and 5% Tween 80 (w/v) at a concentration of 1 mg/kg 6 hours prior to inoculation. We then inoculated young male Syrian hamsters intranasally with  $5 \times 10^4$  plaque forming units (PFUs) of SARS-CoV-2 (JPN/Kanagawa/KUH003) isolated from COVID-19 patient specimens (Fig. 1a)<sup>16</sup>. Analysis of body weight changes after inoculation demonstrated that hamsters infected with SARS-CoV-2 had temporary weight loss which peaked on the 7th day of infection. However, weight loss was suppressed in hamsters orally administered ivermectin prior to inoculation (Fig. 1b). These results indicate that oral administration of 1 mg/kg ivermectin in hamsters acts prophylactically against SARS-CoV-2 infection and prevents weight loss after viral infection.

### Prophylactic administration of ivermectin reduces pulmonary disease in a hamster model of SARS-CoV-2 infection

We next examined the pharmacological effects of ivermectin in the lungs, the primary target of SARS-CoV-2 infection. We observed pulmonary changes associated with viral infection on histopathological examination of hamster lungs on days 3 and 6 of SARS-CoV-2 infection, including thickening of alveolar walls and infiltration of neutrophils. However, ivermectin-treated hamsters had decreased pulmonary inflammation (Fig. 2a). Furthermore, we compared pulmonary virus titers with plaque assays using SARS-

CoV-2-sensitive VeroE6/TMPRSS2 cells<sup>17</sup>. Viral titers in the lungs of ivermectin-treated hamsters were reduced by a factor of 10 compared to vehicle-treated hamsters on days 3 and 6 days after infection (Fig. 2b). These results indicate that prophylactic administration of ivermectin reduces pulmonary injury and viral titers in a hamster model of SARS-CoV-2 infection.

## **Prophylactic administration of ivermectin inhibits pulmonary expression of inflammatory cytokines in response to SARS-CoV-2 infection**

When SARS-CoV-2 infects target cells, viral genomes are detected by viral sensors such as RIG-I, MDA-5, and TLR3 which then induce host innate immune responses<sup>18,19</sup>. Although activation of an appropriate innate immune response is essential for viral elimination, severe cases of COVID-19 are reported to have excessive activation of innate immunity<sup>1,2</sup>. Inappropriate activation of innate immunity leads to excessive production of inflammatory cytokines, which are often lethal to the host. Therefore, quantitative PCR was performed using Syrian hamster-specific primers and probes designed at Takara Bio (Shiga, Japan) to compare mRNA expression levels of several cytokines and interferon-inducible transcription factors in the lung (Supplementary Table.1). Expression of pro-inflammatory cytokines, such as *Il6* in the early stage of viral infection and *Tnf* in the late stage of viral infection, were decreased in ivermectin-treated hamsters (Fig. 3a,b). On the other hand, expression of the immunosuppressive cytokine, *Il10*, or the interferon-inducible transcription factor, *Irf7*, remained unchanged (Fig. 3c d). These results suggest that ivermectin suppresses the expression of inflammatory cytokines associated with SARS-CoV-2 infection at the genetic level.

## **Prophylactic administration of ivermectin reduces the severity of pathological changes associated with SARS-CoV-2 infection**

Ivermectin has been reported to have a variety of pharmacological effects on the body, including anticancer and antiviral activities in addition to anthelmintic activity<sup>20,21</sup>. Ivermectin has been reported to have *in vitro* antiviral activity against HIV and dengue virus<sup>22-24</sup>; however, the *in vivo* antiviral activity of ivermectin remains unclear. In severe cases of COVID-19, elevated plasma D-Dimer levels and decreased zinc levels have been reported<sup>25</sup>. Efficient induction of neutralizing antibodies is crucial for viral elimination during recovery from COVID-19<sup>26</sup>. We therefore examined plasma D-Dimer levels in SAR-CoV-2-infected hamsters prophylactically treated with ivermectin and found no clear difference compared to the vehicle-treated group(Supplementary Fig. 2). We further measured virus neutralizing antibody titer in plasma on 10 day after infection, which we considered the recovery period. Plasma titers of neutralizing antibodies were significantly higher in ivermectin-treated hamsters compared to vehicle-treated hamsters (Fig. 4a). In addition, ivermectin-treated animals had higher zinc concentrations in lung suspensions on day 3 after infection, with a similar trend observed 10 days after infection (Fig. 4b). These results suggest

that prophylactic administration of ivermectin has multiple effects that lead to a reduction in the severity of pathological changes associated with SARS-CoV-2 infection.

## Discussion

In the present study, we demonstrate the efficacy of prophylactic administration of ivermectin in the protection against SARS-CoV-2 infection in a Syrian hamster model. Hamsters orally administered ivermectin prior to infection with SARS-CoV-2 had reduced body weight loss (Fig. 1) and reduced viral titers and inflammation in the lungs, a major target organ of SARS-CoV-2 (Fig. 2). Furthermore, prophylactic administration of ivermectin suppressed the expression of pro-inflammatory cytokines (IL-6 and TNF) reported to be increased in severe cases of COVID-19 (Fig. 3). Moreover, prophylactic administration of ivermectin increased plasma titers of neutralizing antibodies and pulmonary zinc levels leading to suppression of severe COVID-19 (Fig. 4).

We first conducted a preliminary study of the dosage and administration of ivermectin in hamsters as described above. There are several reports of the efficacy of ivermectin administration against coronavirus infection<sup>27,28</sup>; however, we observed no protective effect against SARS-CoV-2 at ivermectin doses lower than 1 mg/kg. The common dose of ivermectin in human clinical practice is 200 µg/kg, a lower dose than required for efficacy against SARS-CoV-2 infection in our hamster model. This difference in the concentration of ivermectin required for efficacy between previous reports and our study may be due to differences in the solvent used for administration or the sex or age of hamsters used. Therefore, the clinical application of ivermectin as a therapy for COVID-19 in humans appears to require careful investigation in clinical trials in addition to *in vivo* studies to determine the most effective dosage, frequency and administration methods.

The mechanism of action of ivermectin in protecting against SARS-CoV-2 infection is currently being investigated in detail using cultured cells and rodent models such as human ACE2 transgenic mice and hamsters. Although we were unable to demonstrate a clear mechanism of action in the present study, we posit the activity of ivermectin is mediated by host immunity as ivermectin is effective when administered as a single dose before viral infection. In addition to activating parasite-specific glutamine-gated chloride channels, ivermectin has been reported to have multiple bioactivities, including inhibition of the interaction between importin  $\alpha/\beta$  and RNA virus component proteins, and structural stabilization of the calcium-activated channel, P2X4 receptor<sup>29</sup>. Of note, an increase in virus-specific neutralizing antibody titers and pulmonary zinc levels following ivermectin administration were observed in the present study (Fig. 4). Changes in intracellular concentrations of divalent metal ions such as zinc and calcium reportedly affect the host immune response<sup>30–33</sup>. Ivermectin interacts with various ion channel proteins to regulate intracellular ion concentrations, suggesting ion-mediated immunomodulatory mechanisms are involved in immune responses to SARS-CoV-2 infection.

In summary, we demonstrate the efficacy of prophylactic administration of ivermectin in a hamster model of SARS-CoV-2 infection. Ivermectin may represent an effective therapeutic option for COVID-19; however,

further *in vitro* and *in vivo* analyses are required to determine the optimal dose and method of administration of ivermectin. High quality clinical trials are required to fully elucidate the mechanism of action of ivermectin and validate the potential of ivermectin as a therapeutic option for the prevention and treatment of COVID-19.

## Materials And Methods

### Hamsters

Three-week-old Male Syrian hamsters were purchased from Japan SLC, Inc. (Hamamatsu, Japan) and used for experiments after a week of quarantine. Hamsters were housed under specific pathogen-free conditions. Animal experiments were approved by the Institutional Animal Care and Use Committee of Kitasato University (approval number: 2020-7), and the experiments were conducted in accordance with the institutional ethical guidelines for animal experiments. We also confirmed that all experimental procedures are reported in accordance with ARRIVE guidelines for the reporting of animal experiments.

### Reagents

Ethanol, polyethylene glycol (PEG) 400, and hydrochloric acid were purchased from Fujifilm Wako Pure Chemical (Osaka, Japan). Tween 80 was purchased from Kanto Chemical (Tokyo, Japan). Metallo Assay Zinc LS was purchased from Metallogenics (Chiba, Japan). Hamster D-Dimer (D2D) ELISA kits were purchased from My BioSource (San Diego, CA). Ivermectin was purchased from Sigma Aldrich (St. Louis, MO).

### SARS-CoV-2 Virus

The SARS-CoV-2 strain, JPN/Kanagawa/KUH003 (accession # LC630936) isolated from patients with COVID-19 admitted to Kitasato University Hospital, was used in this experiment<sup>16</sup>. This study was approved by the Kitasato University Medical Ethics Organization (KMEO; approval numbers: KMEO B20-016-1, KMEO B20-016-2). We also ensured that all processes were carried out in accordance with all relevant guidelines and regulations. The Kitasato University Medical Ethics Organization waived the need for informed consent for the virus strains used in this study because they were derived from anonymized clinical specimens.

### SARS-CoV-2 infection in hamsters

Young male Syrian hamsters were orally administered ivermectin prepared with 5% ethanol (w/v), 10% polyethylene glycol (PEG) 400 (w/v), and 5% Tween 80 (w/v) at a concentration of 1 mg/kg 6 hours prior to inoculation. After 6 hours, hamsters were anesthetized with medetomidine hydrochloride, midazolam, and butorphanol tartrate and infected with  $5 \times 10^4$  PFUs of SARS-CoV-2 (JPN/Kanagawa/KUH003) by intranasal administration.

### Virus titers

Lung tissues were collected at 0, 3, 6, and 10 days after SARS-CoV-2 infection and homogenized using a gentleMACS dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany). Lung homogenates were serially diluted with D-MEM (Fujifilm Wako Pure Chemical) supplemented with 2% foetal bovine serum (Life Technologies, Carlsbad, CA) and antibiotics (100 IU/mL penicillin and 100 µg/mL streptomycin; Fujifilm Wako Pure Chemical). For plaque assays, VeroE6/TMPRSS2 cells (obtained from JCRB cell bank, Osaka, Japan) were plated at  $4 \times 10^5$  cells in a flat-bottomed 6-well plate (Corning, Corning, NY) a day before infection. Supernatants from serially diluted lung homogenates were used to infect VeroE6/TMPRSS2 cells at 37°C for 1 hour. Cells were subsequently overlaid with D-MEM mixed with 1% carboxymethyl cellulose sodium (Fujifilm Wako Pure Chemical). Plaques were visualized by staining with methylene blue (Nacalai tesque, Kyoto, Japan), and counted 3 days after infection.

## **Histology**

Hamsters were euthanized by intraperitoneal administration of sodium pentobarbital at 0, 3, 6, and 10 days after SARS-CoV-2 infection and lungs were collected. Paraffin embedding and hematoxylin and eosin staining of tissues were performed using standard methodologies.

## **qPCR analysis for mRNA expression**

Total RNA was extracted from cells using the ISOGEN (NIPPON GENE, Tokyo, Japan). cDNA was synthesized from mRNA using One Step PrimeScript III RT-qPCR Mix with UNG (Takara Bio, Shiga, Japan). RT products were directly subjected to qPCR in a 7500 real-time PCR system (Applied Biosystems, Foster City, CA, USA) using Syrian hamster-specific primers and probes designed at Takara Bio (Supplementary Table 1).

## **Zinc concentration measurements**

After adding hydrochloric acid to lung homogenates to form an acidic mixture at approximately 0.1 M, the zinc concentration was determined using the Metallo Assay Zinc LS according to the manufacturer's instructions.

## **Neutralizing antibody titer measurements**

Plasma was serially 2-fold diluted in medium and mixed with an equal volume of a virus suspension containing approximately 200 PFU/100 µL. Mixtures were incubated at 37°C for 1 hour. Cells were then inoculated in 96-well flat-bottomed plates and incubated in an atmosphere of 5% CO<sub>2</sub> in air at 37°C for 3 days. For each serum dilution, tests were duplicated. Neutralizing antibody titers were expressed as a reciprocal of the highest dilution of the test sera that inhibited the cytopathic effect completely.

## **Statistical analysis**

Statistical analyses were performed using GraphPad Prism (GraphPad, San Diego, CA, USA). Student's t-test was used to evaluate differences between datasets. Values are presented as means ± SEM. P-values less than 0.05 were considered statistically significant.

# Declarations

## Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Acknowledgements

We are grateful to Distinguished Emeritus Professor Satoshi Ōmura (Kitasato University) for his helpful support and valuable suggestions. We thank Kei Haga, Reiko Takai-Todaka, and Kazuhiko Katayama for providing the SARS-CoV-2 strain, JPN/Kanagawa/KUH003. We also thank Wataru Ando, Anna Kitajima, Shizuka Ishida, Hidero Kitasato, Makoto Kubo, Shotaro Maehana, Taiga Yamazaki, and Takashi Fukuyama for helpful discussions and technical support.

## Funding information

This study was supported by a COVID-19 Kitasato Project, JSPS KAKENHI grant numbers JP16K09585, JP19K08935, JP22K08586, a GSK Japan Research Grant 2017, and the Kawano Masanori Memorial Public Interest Incorporated Foundation for Promotion of Pediatrics to T.U. This study was also supported by a Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development, AMED, under grant number JP20fk0108158 to H.H.

## Author Contributions

T.U., T.T., H.M., and N.K. performed the experiments. T.U., T.T., H.M., N.K., and H.H. analyzed the data. T.T. and H.H. supervised this work. T.U. directed the project and wrote the manuscript. All authors reviewed the manuscript.

## Conflicts of interest

The authors declare that there are no conflicts of interest.

## Ethical statement

This study was approved by the Kitasato University Medical Ethics Organization (KMEO) (approval numbers: KMEO B20-016-1, KMEO B20-016-2). We also ensured that all processes were carried out in accordance with all relevant guidelines and regulations. The Kitasato University Medical Ethics Organization waived the need for informed consent for the virus strains used in this study because they were derived from anonymized clinical specimens.

Animal experiments were approved by the Institutional Animal Care and Use Committee of Kitasato University (approval number: 2020-7), and the experiments were conducted in accordance with the

institutional ethical guidelines for animal experiments. We also confirmed that all experimental procedures are reported in accordance with ARRIVE guidelines for the reporting of animal experiments.


## References

1. Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **324**, 782–793 (2020).
2. Ramos-Casals, M., Brito-Zerón, P. & Mariette, X. Systemic and organ-specific immune-related manifestations of COVID-19. *Nat Rev Rheumatol.* **17**, 315–332 (2021).
3. Puntmann, V. O. *et al.* Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered from Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology* **5**, 1265–1273 (2020).
4. Ladds, E. *et al.* Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. *BMC Health Services Research* **20**, 1144 (2020).
5. Sharma, O., Sultan, A. A., Ding, H. & Trigg, C. R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Front Immunol.* **11**, 585354 (2020).
6. Rawat, K., Kumari, P. & Saha, L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. *Eur J Pharmacol.* **892**, 173751 (2021).
7. Collier, D. A. *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* **593**, 136–141 (2021).
8. Israel, A. *et al.* Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study. *BMJ* **375**, e067873 (2021).
9. Ōmura, S. & Crump, A. The life and times of ivermectin - A success story. *Nat Rev Microbiol.* **2**, 984–989 (2004).
10. Crump, A. & Omura, S. Ivermectin, “Wonder drug” from Japan: The human use perspective. *Proc Jpn Acad Ser B Phys Biol Sci.* **87**, 13–28 (2011).
11. Caly, L., Druce, J. D., Catton, M. G., Jans, D. A. & Wagstaff, K. M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* **178**, 104787 (2020).
12. Popp, M. *et al.* Ivermectin for preventing and treating COVID-19. *Cochrane Database Syst Rev.* **6**, CD015017 (2022).
13. Sia, S. F. *et al.* Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **583**, 834–838 (2020).
14. Imai, M. *et al.* Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. *Proc Natl Acad Sci U S A.* **117**, 16587–16595 (2020).
15. Chan, J. F.-W. *et al.* Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis.* **71**, 2428–2446 (2020).

16. Ebisudani, T. *et al.* Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. *Cell Rep.* **35**, 109218 (2021).
17. Matsuyama, S. *et al.* Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. *Proc Natl Acad Sci U S A.* **117**, 7001–7003 (2020).
18. Schultze, J. L. & Aschenbrenner, A. C. COVID-19 and the human innate immune system. *Cell* **184**, 1671–1692 (2021).
19. Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G. & Schultz-Cherry, S. Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract. *Nat Rev Microbiol.* **19**, 425–441 (2021).
20. Nishio, M. *et al.* Dysregulated YAP1/TAZ and TGF- $\beta$  signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. *Proc Natl Acad Sci U S A* **113**, E71-80 (2016).
21. Nambara, S. *et al.* Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. *Oncotarget* **8**, 107666–107677 (2017).
22. Wagstaff, K. M., Sivakumaran, H., Heaton, S. M., Harrich, D. & Jans, D. A. Ivermectin is a specific inhibitor of importin  $\alpha/\beta$ -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem J* **443**, 851–6 (2012).
23. Xu, T. L. *et al.* Antivirus effectiveness of ivermectin on dengue virus type 2 in *Aedes albopictus*. *PLoS Negl Trop Dis* **12**, e0006934 (2018).
24. Yang, S. N. Y. *et al.* The broad spectrum antiviral ivermectin targets the host nuclear transport importin  $\alpha/\beta$  heterodimer. *Antiviral Res* **177**, 104760 (2020).
25. Stratton, C. W., Tang, Y. W. & Lu, H. Pathogenesis-directed therapy of 2019 novel coronavirus disease. *J Med Virol* **93**, 1320–1342 (2021).
26. Wang, P. *et al.* SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. *Emerg Microbes Infect* **9**, 2091–2093 (2020).
27. Melo, G. D. de *et al.* Attenuation of clinical and immunological outcomes during SARS-CoV-2 infection by ivermectin. *EMBO Mol Med.* **13**, e14122 (2021).
28. Arévalo, A. P. *et al.* Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. *Sci Rep.* **11**, 7132 (2021).
29. Kaur, H. *et al.* Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes. *Pharmacol Rep.* **73**, 736–749 (2021).
30. Hirano, T. *et al.* Roles of Zinc and Zinc Signaling in Immunity: Zinc as an Intracellular Signaling Molecule. *Adv Immunol.* **97**, 149–176 (2008).
31. Vig, M. & Kinet, J. P. Calcium signaling in immune cells. *Nat Immunol.* **10**, 21–27 (2009).
32. te Velthuis, A. J. W. *et al.* Zn<sup>2+</sup> + Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture. *PLoS Pathog.* **6**, e1001176 (2010).

33. Kumar, A., Kubota, Y., Chernov, M. & Kasuya, H. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. *Med Hypotheses*. **144**, 109848 (2020).


## Figures



**Figure 1**

**Figure 1**


**Prophylactic administration of ivermectin prevents weight loss in a hamster model of SARS-CoV-2 infection.** (a) Schematic of the experimental design. (b) Bodyweight change in Syrian hamsters following SARS-CoV-2 infection. Both vehicle-treated and ivermectin (IVM)-treated hamsters ( $n = 6$  per group) were infected by intranasal injection of  $5 \times 10^4$  plaque-forming units (PFU) of SARS-CoV-2 followed by assessments for bodyweight change. Hamsters without viral infection,  $n = 3$  per group. Data are presented as the means  $\pm$  SEM. \* $P < 0.05$  by Student's t-test.



**Figure 2**

**Figure 2**


**Prophylactic administration of ivermectin reduces the severity of pulmonary disease in a hamster model of SARS-CoV-2 infection.** (a) Hematoxylin and eosin staining of the lungs on days 0, 3, 6 and 10 after SARS-CoV-2 infection. Bar = 50  $\mu$ m. (b) Viral titers in infected lungs. Lungs from vehicle-treated or IVM-treated hamsters infected with SARS-CoV-2 on days 0, 3, 6 and 10 (n = 5 per group) were homogenized and virus titers were quantified by plaque assay in VeroE6/TMPRSS2 cells. N.D., not detected. Data are presented as the means  $\pm$  SEM. \*P < 0.05 by Student's t-test.



**Figure 3**

**Figure 3**

**Prophylactic administration of ivermectin inhibits pulmonary inflammatory cytokine expression following SARS-CoV-2 infection.** (a) *Il6*, (b) *Tnf*, (c) *Il10*, and (d) *Irf7* mRNA expression levels in lungs of vehicle-treated or IVM-treated hamsters (n = 5 per group) after SARS-CoV-2 infection. Data are presented as the means  $\pm$  SEM of duplicates. \*P < 0.05 by Student's t-test.



**Figure 4**

**Figure 4**

**Prophylactic administration of ivermectin reduces the severity of pathological changes associated with SARS-CoV-2 infection.** (a) Plasma titers of neutralizing antibodies on day 0 and 10 in vehicle-treated or IVM-treated hamsters (n = 5 per group) infected with SARS-CoV-2. Neutralizing antibody titers are expressed as a reciprocal of the highest dilution of the test plasma that completely inhibited the cytopathic effect. (b) Zinc concentrations in lungs from vehicle-treated or IVM-treated hamsters (n = 5 per group) after SARS-CoV-2 infection. Data are presented as the means ± SEM of duplicates. \*P < 0.05 by Student's t-test.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [IVMSARSCoV2SI220830.pdf](#)